Chemomab Therapeutics (NASDAQ:CMMB) Upgraded at Zacks Research

Zacks Research upgraded shares of Chemomab Therapeutics (NASDAQ:CMMB) from a hold rating to a strong-buy rating in a research report report published on Monday morning,Zacks.com reports.

A number of other equities research analysts have also issued reports on CMMB. Weiss Ratings restated a “sell (e+)” rating on shares of Chemomab Therapeutics in a research report on Wednesday, October 8th. Wall Street Zen upgraded Chemomab Therapeutics to a “hold” rating in a research report on Saturday, October 11th. Finally, Oppenheimer upped their price target on Chemomab Therapeutics from $10.00 to $25.00 and gave the company an “outperform” rating in a research report on Wednesday, August 27th. One analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $26.50.

Chemomab Therapeutics Price Performance

Shares of Chemomab Therapeutics stock opened at $3.09 on Monday. The business has a 50 day simple moving average of $3.12 and a two-hundred day simple moving average of $4.19. Chemomab Therapeutics has a 12 month low of $2.39 and a 12 month high of $9.84. The stock has a market capitalization of $15.98 million, a P/E ratio of -1.31 and a beta of 0.57.

Chemomab Therapeutics (NASDAQ:CMMB) last announced its earnings results on Thursday, August 14th. The company reported ($0.36) EPS for the quarter, beating analysts’ consensus estimates of ($0.80) by $0.44. As a group, research analysts anticipate that Chemomab Therapeutics will post -1 EPS for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Chemomab Therapeutics stock. Virtu Financial LLC grew its position in shares of Chemomab Therapeutics Ltd. Sponsored ADR (NASDAQ:CMMB) by 113.2% during the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 30,803 shares of the company’s stock after purchasing an additional 16,358 shares during the period. Virtu Financial LLC owned approximately 0.21% of Chemomab Therapeutics worth $34,000 as of its most recent SEC filing. 46.05% of the stock is owned by institutional investors.

About Chemomab Therapeutics

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc).